AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2024

Sep 11, 2024

33148_dirs_2024-09-11_67fab1c3-8939-4949-8f41-dd6368eeb096.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2024-09-09

Reporting Person: Dolsten Mikael (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-09-09	Stock Option (Right to Buy)	$19.73	A	27545	Acquired	2034-09-09	Common Stock (27545)	Direct
2024-09-09	Stock Option (Right to Buy)	$19.73	A	22988	Acquired	2034-09-09	Common Stock (22988)	Direct

Footnotes

F1: This option represents a right to purchase a total of 27,545 shares of the Issuer's common stock, which will vest in equal monthly installments over a three-year period, such that all of the shares underlying this option will be fully vested on September 9, 2027.

F2: This option represents a right to purchase a total of 22,988 shares of the Issuer's common stock, which will fully vest on September 9, 2025.